Equities research analysts predict that Forty Seven Inc (NASDAQ:FTSV) will report earnings of ($0.66) per share for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Forty Seven’s earnings, with estimates ranging from ($0.71) to ($0.60). The firm is scheduled to issue its next quarterly earnings results on Tuesday, February 19th.

According to Zacks, analysts expect that Forty Seven will report full year earnings of ($3.42) per share for the current fiscal year, with EPS estimates ranging from ($4.03) to ($2.38). For the next financial year, analysts forecast that the company will report earnings of ($2.77) per share, with EPS estimates ranging from ($2.93) to ($2.44). Zacks’ earnings per share calculations are an average based on a survey of research analysts that cover Forty Seven.

Forty Seven (NASDAQ:FTSV) last announced its quarterly earnings data on Tuesday, November 13th. The company reported ($0.71) earnings per share for the quarter, missing the consensus estimate of ($0.54) by ($0.17).

FTSV has been the subject of a number of recent analyst reports. Zacks Investment Research lowered Forty Seven from a “hold” rating to a “sell” rating in a report on Tuesday. HC Wainwright set a $21.00 target price on Forty Seven and gave the company a “buy” rating in a report on Wednesday, January 23rd. FIG Partners initiated coverage on Forty Seven in a report on Friday, February 1st. They set a “buy” rating and a $30.00 target price for the company. ValuEngine raised Forty Seven from a “hold” rating to a “buy” rating in a report on Thursday, November 1st. Finally, BTIG Research initiated coverage on Forty Seven in a report on Friday, December 21st. They set a “buy” rating and a $36.00 target price for the company. One investment analyst has rated the stock with a sell rating, one has given a hold rating and seven have issued a buy rating to the company’s stock. Forty Seven currently has a consensus rating of “Buy” and an average price target of $27.71.

FTSV traded up $0.06 during trading hours on Monday, hitting $15.48. The stock had a trading volume of 139,969 shares, compared to its average volume of 149,541. Forty Seven has a 1 year low of $12.02 and a 1 year high of $23.83.

In other Forty Seven news, Director Irving Weissman sold 10,000 shares of Forty Seven stock in a transaction dated Wednesday, January 9th. The stock was sold at an average price of $17.05, for a total transaction of $170,500.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Chris H. Takimoto sold 8,000 shares of Forty Seven stock in a transaction dated Friday, January 4th. The shares were sold at an average price of $15.55, for a total value of $124,400.00. The disclosure for this sale can be found here. Insiders have sold a total of 115,363 shares of company stock valued at $1,767,688 in the last ninety days.

Institutional investors and hedge funds have recently modified their holdings of the company. Citadel Advisors LLC boosted its position in shares of Forty Seven by 144.4% during the 3rd quarter. Citadel Advisors LLC now owns 572,923 shares of the company’s stock valued at $8,548,000 after acquiring an additional 338,489 shares during the last quarter. JPMorgan Chase & Co. boosted its position in shares of Forty Seven by 51.2% during the 3rd quarter. JPMorgan Chase & Co. now owns 346,066 shares of the company’s stock valued at $5,164,000 after acquiring an additional 117,142 shares during the last quarter. Millennium Management LLC bought a new stake in shares of Forty Seven during the 2nd quarter valued at about $1,940,000. BlackRock Inc. bought a new stake in shares of Forty Seven during the 2nd quarter valued at about $548,000. Finally, Credit Suisse AG bought a new stake in shares of Forty Seven during the 3rd quarter valued at about $209,000. Hedge funds and other institutional investors own 42.96% of the company’s stock.

About Forty Seven

Forty Seven Inc, a clinical-stage immuno-oncology company, focuses on developing therapies to activate macrophages for the treatment of cancer. It is developing 5F9, a humanized IgG4 subclass monoclonal antibody against CD47 that is in Phase 1b/2 clinical trials used for the treatment of cancer; and FSI-189, an antibody that binds to SIRPa for the treatment of solid tumors.

Further Reading: Analyst Ratings Trading

Get a free copy of the Zacks research report on Forty Seven (FTSV)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Forty Seven (NASDAQ:FTSV)

Receive News & Ratings for Forty Seven Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Forty Seven and related companies with MarketBeat.com's FREE daily email newsletter.